Reuters

Lazard raises Vivus to buy on weight-loss drug prospects

(Reuters) - Lazard Capital Markets raised its rating on Vivus Inc to "buy" from "neutral," saying the drugmaker's weight-loss pill was set to a big launch despite a potential patent dispute with Johnson & Johnson.
Read Full Story